Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

ecopipamPositive

AI Analysis

Summary

Teva Pharmaceuticals announced publication of a comprehensive review in the Journal of Child Neurology examining ecopipam, a first-in-class selective D1 receptor antagonist, and its potential therapeutic mechanism for treating tics in pediatric Tourette syndrome patients.

Outcome Details

Journal of Child Neurology published comprehensive review on ecopipam's mechanism of action in Tourette syndrome

Importance:3/10

Sentiment:

0.30

Tourette syndromepediatricdopamine antagonistD1 receptorpublication

Related Companies

$TEVA

Read the original article

Published by GlobeNewswire Clinical Studies on October 2, 2026 12:00 PM

Read Original